Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021)

Nautilus Biotechnology has reported Non-Current Deffered Revenue over the past 2 years, most recently at $5.2 million for Q1 2021.

  • Quarterly results put Non-Current Deffered Revenue at $5.2 million for Q1 2021, changed N/A from a year ago — trailing twelve months through Mar 2021 was $5.2 million (changed N/A YoY), and the annual figure for FY2020 was $5.2 million, changed.
  • Non-Current Deffered Revenue reached $5.2 million in Q1 2021 per NAUT's latest filing, roughly flat from $5.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $5.2 million in Q3 2020 and bottomed at $5.2 million in Q3 2020.